| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3800338 | Medicina Clínica | 2014 | 10 Pages |
Abstract
Our results suggest an increased risk of hepatotoxicity in patients receiving endothelin receptor antagonists. Given the limited data available for endothelin receptor antagonists other than bosentan, it is not possible to draw firm conclusions about the individual risk associated for the remaining endothelin receptor antagonists.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Diego MacÃas Saint-Gerons, César de la Fuente Honrubia, Dolores Montero Corominas, Ferrán Catalá-López,